Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin)\, the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation DisordersEstablished UltraCare® Program Provides Ongoing Patient Support Services